文献速递类风湿关节炎

类风湿关节炎达标治疗策略中最佳目标是什么?一项系统评价与Meta回归分析的结果

What is the best target in a treat-to-target strategy in rheumatoid arthritis? Results from a systematic review and meta-regression analysis.
PubMed 文献 · RMD Open · 2023-01-01

该系统评价与Meta回归分析检索Cochrane、Embase和(pre)MEDLINE数据库(截至2022年6月1日),纳入2003年后应用达标治疗≥12个月的随机对照试验和队列研究,从115个治疗臂中提取数据。结果显示,以SDAI/CDAI低疾病活动度为目标在DAS缓解和SDAI/CDAI/Boolean缓解结局上优于以DAS低疾病活动度为目标;以SDAI/CDAI低疾病活动度为目标在SDAI/CDAI/Boolean缓解和平均SDAI/CDAI上也显著优于以DAS缓解为目标。以DAS缓解而非DAS低疾病活动度为目标仅改善DAS缓解百分比,且仅在达标治疗2-3年后才有统计学显著性。健康评定问卷和影像学进展方面未见差异。

要点

  • 以SDAI/CDAI低疾病活动度为目标在多个临床缓解结局上优于以DAS低疾病活动度为目标。
  • 以DAS缓解而非DAS低疾病活动度为目标仅改善DAS缓解百分比,且仅在2-3年后有统计学显著性。
  • 健康评定问卷和影像学进展在各目标间未见差异。

核心结论

  • 以SDAI/CDAI低疾病活动度为目标,其次以DAS缓解为目标,在若干临床结局上可能优于以DAS低疾病活动度为目标。
  • 由于存在残余混杂风险以及缺乏关于(过度)治疗和安全性的数据,未来研究应旨在直接且全面地比较不同目标。

研究设计与样本

  • 系统评价与Meta回归分析,检索Cochrane、Embase和(pre)MEDLINE数据库(2022年6月1日),纳入2003年后应用达标治疗≥12个月的随机对照试验和队列研究。
  • 从个体达标治疗研究臂提取数据,使用Cochrane协作工具评估偏倚风险,采用Meta回归评估所用目标对临床和影像学结局的影响,并校正研究间和研究内异质性。
  • Meta回归分析共使用115个治疗臂。
  • PROSPERO注册号:CRD42021249015。

主要发现

  • 以SDAI/CDAI低疾病活动度为目标在DAS缓解和SDAI/CDAI/Boolean缓解结局上,1-3年内统计学优于以DAS低疾病活动度为目标。
  • 以SDAI/CDAI低疾病活动度为目标在SDAI/CDAI/Boolean缓解(1-3年内)和平均SDAI/CDAI(1年内)上均显著优于以DAS缓解为目标。
  • 以DAS缓解而非DAS低疾病活动度为目标仅改善DAS缓解患者百分比,且仅在达标治疗2-3年后才达统计学显著。
  • 健康评定问卷和影像学进展方面未观察到差异。

局限性

  • 存在残余混杂风险。
  • 缺乏关于(过度)治疗和安全性的数据。
  • 未来研究应旨在直接且全面地比较不同目标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: A treat-to-target (T2T) strategy has been shown to be superior to usual care in rheumatoid arthritis (RA), but the optimal target remains unknown. Targets are based on a disease activity measure (eg, Disease Activity Score-28 (DAS28), Simplified Disease Activity Indices/Clinical Disease Activity Indices (SDAI/CDAI), and a cut-off such as remission or low disease activity (LDA). Our aim was to compare the effect of different targets on clinical and radiographic outcomes. METHODS: Cochrane, Embase and (pre)MEDLINE databases were searched (1 June 2022) for randomised controlled trials and cohort studies after 2003 that applied T2T in RA patients for ≥12 months. Data were extracted from individual T2T study arms; risk of bias was assessed with the Cochrane Collaboration tool. Using meta-regression, we evaluated the effect of the target used on clinical and radiographic outcomes, correcting for heterogeneity between and within studies. RESULTS: 115 treatment arms were used in the meta-regression analyses. Aiming for SDAI/CDAI-LDA was statistically superior to targeting DAS-LDA regarding DAS-remission and SDAI/CDAI/Boolean-remission outcomes over 1-3 years. Aiming for SDAI/CDAI-LDA was also significantly superior to DAS-remission regarding both SDAI/CDAI/Boolean-remission (over 1-3 years) and mean SDAI/CDAI (over 1 year). Targeting DAS-remission rather than DAS-LDA only improved the percentage of patients in DAS-remission, and only statistically significantly after 2-3 years of T2T. No differences were observed in Health Assessment Questionnaire and radiographic progression. CONCLUSIONS: Targeting SDAI/CDAI-LDA, and to a lesser extent DAS-remission, may be superior to targeting DAS-LDA regarding several clinical outcomes. However, due to the risk of residual confounding and the lack of data on (over)treatment and safety, future studies should aim to directly and comprehensively compare targets. PROSPERO REGISTRATION NUMBER: CRD42021249015.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Messelink MA, den Broeder AA, Marinelli FE, et al. What is the best target in a treat-to-target strategy in rheumatoid arthritis? Results from a systematic review and meta-regression analysis. RMD Open. 2023. PMID: 37116986. doi:10.1136/rmdopen-2023-003196

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。